CDTX Latest Press Releases

-- December 18, 2025 --

Halper Sadeh LLC Encourages EB, KPLT, WBD, CDTX Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 3:25 PM

-- December 17, 2025 --

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 12:06 PM

-- December 10, 2025 --

Halper Sadeh LLC Encourages CADE, MRSN, CDTX Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 3:01 PM

-- December 8, 2025 --

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 3:24 PM

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI PRNewswire 2:40 PM

-- November 28, 2025 --

Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 12:37 PM

-- November 27, 2025 --

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN PRNewswire 11:11 PM

Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 6:52 PM

-- November 24, 2025 --

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations Globe Newswire 8:00 AM

-- November 22, 2025 --

Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 6:03 AM

-- November 21, 2025 --

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX PRNewswire 5:30 PM

-- November 17, 2025 --

Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 12:00 PM

-- November 16, 2025 --

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX Business Wire 6:49 PM

-- November 14, 2025 --

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 3:19 PM

Shareholder Alert: The Ademi Firm investigates whether Cidara Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders PRNewswire 10:08 AM

CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders Business Wire 8:06 AM

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent Business Wire 6:45 AM

-- November 6, 2025 --

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Globe Newswire 4:07 PM

-- October 28, 2025 --

Cidara Therapeutics to Participate in November Investor Conferences Globe Newswire 8:00 AM

-- October 23, 2025 --

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 Globe Newswire 4:05 PM

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10?? ESWI Influenza Conference 2025 Globe Newswire 8:00 AM

-- October 21, 2025 --

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 Globe Newswire 8:00 AM

-- October 13, 2025 --

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 Globe Newswire 8:00 AM

-- October 10, 2025 --

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 Globe Newswire 8:00 AM

-- October 9, 2025 --

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention Globe Newswire 8:00 AM

-- October 2, 2025 --

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic Globe Newswire 4:01 PM

-- September 25, 2025 --

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations Globe Newswire 4:01 PM

-- September 24, 2025 --

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza Globe Newswire 7:00 AM

-- September 17, 2025 --

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting Globe Newswire 8:00 AM

-- September 4, 2025 --

Cidara Therapeutics to Participate in September Investor Conferences Globe Newswire 8:00 AM

-- September 3, 2025 --

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting Globe Newswire 8:00 AM

-- August 7, 2025 --

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Globe Newswire 4:05 PM